Skip to main content

Table 1 Characteristics of phase 2 trial sites

From: A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine

Site

Participants (RTS,S)

Active vaccine

Median age (IQR)

Parasite prevalencea

Schedule

Peak anti-CSP titre (95% range)

Gambia [[12]]

250 (136)

RTS,S/AS02A

24 (19 to 34) years

70%

0,1,5,14 months

25 (13 to 43) μg/mL

Kisumu, Kenya [[13]]

250 (159)

RTS,S/AS02A and RTS,S/AS01B

25 (21 to 29) years

60%

0,1,2 months

34 (2 to 210) EU/mL

Manhica, Mozambique (cohort 1) [[7],[14]]

1,589 (768)

RTS,S/AS02A

35 (24 to 48) months

40%

0,1,2 months

191 (9 to 916) EU/mL

Ilha Josina, Mozambique (cohort 2) [[7],[14]]

411 (196)

RTS,S/AS02A

36 (24 to 45) months

45%

0,1,2 months

266 (16 to 1,390) EU/mL

Kilifi, Kenya [[6],[15]]

447 (209)

RTS,S/AS01E

11 (8 to 14) months

35%

0,1,2 months

580 (104 to 1,922) EU/mL

Korogwe, Tanzania [[6]]

447 (224)

RTS,S/AS01E

12 (9 to 15) months

15%

0,1,2 months

493 (138 to 1,768) EU/mL

Kintampo, Ghana [[10]]

180 (180)

RTS,S/AS02D and RTS,S/AS01E

11 (8 to 14) months

80%

0,1,2 and 0,1,7 months

465 (73 to 2,632)b EU/mL

Kumasi, Ghana [[10]]

270 (270)

RTS,S/AS02D and RTS,S/AS01E

11 (7 to 13) months

35%

0,1,2 and 0,1,7 months

460 (84 to 1,785)b EU/mL

Lambaréné, Gabon [[9]]

180 (180)

RTS,S/AS02D and RTS,S/AS01E

38 (31 to 48) months

5%

0,1,2 months

198 (32 to 888) EU/mL

Bagamoyo, Tanzania [[8]]

209 (136)

RTS,S/AS01E

1.8 (1.7 to 1.9) months

30%

0,1,2 and 0,1,7 monthsc

167 (14 to 934)b EU/mL

Lambaréné, Gabon [[8]]

215 (139)

RTS,S/AS01E

1.5 (1.4 to 1.7) months

5%

0,1,2 and 0,1,7 monthsc

337 (97 to 1,836)bEU/mL

Kintampo, Ghana [[8]]

81 (52)

RTS,S/AS01E

1.6 (1.5 to 1.8) months

80%

0,1,2 and 0,1,7 monthsc

70 (11 to 455)b EU/mL

Mozambique infants [[16]]

214 (98)

RTS,S/AS02D

1.8 (1.8 to 2.1) months

45%

0,1,2 months

211 (6 to 1,008) EU/mL

Bagamoyo, Tanzania [[11]]

340 (157)

RTS,S/AS02D

1.9 (1.8 to 2) months

30%

0,1,2 monthsc

87 (1 to 572)b EU/mL

  1. For participants receiving at least one dose of RTS,S the peak anti-CSP antibody titre following vaccination is presented as the median and 95% range within the cohort at each trial site. aAge-corrected parasite prevalence in 2- to 10-year olds taken from Malaria Atlas Project [[17]]; bindicates peak anti-CSP antibody titre in the cohort vaccinated through a 0, 1, 2 month schedule; cindicates co-administration with the EPI vaccines (diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenza type b). CSP, circumsporozoite protein; EPI, expanded programme on immunization; EU, ELISA units; IQR, interquartile range.
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us